Abstract
Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculous therapy. Physicians should be aware of the increased risk of a paradoxical response in this population and should consider the use of corticosteroids when a paradoxical reaction is suspected.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use*
-
Antitubercular Agents / adverse effects*
-
Antitubercular Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Crohn Disease / drug therapy
-
Female
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Male
-
Middle Aged
-
Retrospective Studies
-
Spondylitis, Ankylosing / drug therapy
-
Tuberculosis, Pulmonary / drug therapy*
Substances
-
Antibodies, Monoclonal
-
Antitubercular Agents
-
Immunosuppressive Agents
-
Infliximab